scholarly article | Q13442814 |
P2093 | author name string | Albert Y Liu | |
C Bradley Hare | |||
Julia L Marcus | |||
Stephanie E Cohen | |||
Jonathan E Volk | |||
Oliver Bacon | |||
Jess Pinder | |||
P2860 | cites work | STD/HIV risk among adults in the primary care setting: are we adequately addressing our patients' needs? | Q39943298 |
The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs | Q41222547 | ||
Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women | Q41601407 | ||
Incident Hepatitis C Virus Infections Among Users of HIV Preexposure Prophylaxis in a Clinical Practice Setting | Q42847376 | ||
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study | Q46333832 | ||
Detection of acute HIV infections in high-risk patients in California. | Q46438877 | ||
STD/HIV Prevention Practices Among Primary Care Clinicians: Risk Assessment, Prevention Counseling, and Testing | Q57758880 | ||
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men | Q24612082 | ||
Preexposure prophylaxis for HIV prevention: where have we been and where are we going? | Q26825042 | ||
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women | Q28270788 | ||
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial | Q28292876 | ||
Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco | Q28476730 | ||
No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis | Q28537713 | ||
Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco | Q28658226 | ||
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana | Q29620078 | ||
High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project | Q30877918 | ||
Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection | Q33185974 | ||
Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection | Q33948938 | ||
Availability of HIV postexposure prophylaxis services in Los Angeles County | Q34071050 | ||
HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial | Q34249966 | ||
Two years of Truvada for pre-exposure prophylaxis utilization in the US. | Q34477239 | ||
Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial | Q35163040 | ||
Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis | Q35473551 | ||
Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials | Q35558205 | ||
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial | Q36048957 | ||
Risk compensation: the Achilles' heel of innovations in HIV prevention? | Q36417699 | ||
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial | Q36426896 | ||
No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting | Q36735089 | ||
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. | Q37042094 | ||
Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services | Q37296618 | ||
Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States | Q37524778 | ||
Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis | Q37577222 | ||
Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis | Q37665912 | ||
Evaluation of self-collected versus clinician-collected swabs for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae pharyngeal infection among men who have sex with men. | Q37850060 | ||
High performance and acceptability of self-collected rectal swabs for diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in men who have sex with men and women | Q37854586 | ||
Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: lessons learned from trials and treatment studies | Q38068661 | ||
P433 | issue | 2 | |
P921 | main subject | lessons learned | Q1673259 |
P304 | page(s) | 116-124 | |
P577 | publication date | 2016-02-22 | |
P1433 | published in | Current HIV/AIDS reports | Q26842190 |
P1476 | title | Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings | |
P478 | volume | 13 |
Q90292815 | A Cross-sectional Survey of Internal Medicine Resident Knowledge, Attitudes, Behaviors, and Experiences Regarding Pre-Exposure Prophylaxis for HIV Infection |
Q63785465 | Access to HIV Pre-exposure Prophylaxis in Practice Settings: a Qualitative Study of Sexual and Gender Minority Adults' Perspectives |
Q38850925 | Brief Report: Medication Sharing Is Rare Among African HIV-1 Serodiscordant Couples Enrolled in an Efficacy Trial of Oral Pre-exposure Prophylaxis (PrEP) for HIV-1 Prevention |
Q38657576 | Challenges in Translating PrEP Interest into Uptake in an Observational Study of Young Black MSM. |
Q47568567 | Correlates of Linkage to HIV Pre-exposure Prophylaxis (PrEP) among HIV Testing Clients |
Q92918284 | Global implementation of PrEP for HIV prevention: setting expectations for impact |
Q47303141 | HIV Care Providers' Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults |
Q40049033 | HIV pre-exposure prophylaxis implementation at local health departments: a statewide assessment of activities and barriers |
Q40446068 | Healthcare Access and PrEP Continuation in San Francisco and Miami After the US PrEP Demo Project |
Q59358130 | Impact of Providing Preexposure Prophylaxis for Human Immunodeficiency Virus at Clinics for Sexually Transmitted Infections in Baltimore City: An Agent-based Model |
Q40135129 | Interest in Long-Acting Injectable PrEP in a Cohort of Men Who have Sex with Men in China |
Q58574198 | Location location location: an exploration of disparities in access to publicly listed pre-exposure prophylaxis clinics in the United States |
Q89415225 | Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China |
Q64245540 | Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care |
Q38985811 | Pre-Exposure Prophylaxis: A Narrative Review of Provider Behavior and Interventions to Increase PrEP Implementation in Primary Care |
Q33656112 | Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation |
Q48567383 | Preexposure Prophylaxis of HIV Infection: the Role of Clinical Practices in Ending the HIV Epidemic |
Q92343676 | Preferences for implementation of HIV pre-exposure prophylaxis (PrEP): Results from a survey of primary care providers |
Q55420581 | Provider Adherence to Pre-exposure Prophylaxis Monitoring Guidelines in a Large Primary Care Network. |
Q46771194 | Randomized Controlled Trial of Daily Text Messages To Support Adherence to PrEP In At-Risk for HIV Individuals: The TAPIR Study. |
Q92158771 | Same-Day HIV Pre-Exposure Prophylaxis (PrEP) Initiation During Drop-in Sexually Transmitted Diseases Clinic Appointments Is a Highly Acceptable, Feasible, and Safe Model that Engages Individuals at Risk for HIV into PrEP Care |
Q64110144 | Scaling-up PrEP Delivery in Sub-Saharan Africa: What Can We Learn from the Scale-up of ART? |
Q36286229 | Social, structural, behavioral and clinical factors influencing retention in Pre-Exposure Prophylaxis (PrEP) care in Mississippi |
Q38641903 | The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women |
Q42271267 | Top Questions in ID: Pre-exposure Prophylaxis for HIV. |
Q38967290 | Uptake of HIV Pre-Exposure Prophylaxis (PrEP) in a National Cohort of Gay and Bisexual Men in the United States. |